Vistin Pharma ASA (OSL:VISTN)
Norway
· Delayed Price · Currency is NOK 24.50
-0.50 (-2.00%)
At close: May 8, 2025
Vistin Pharma ASA Revenue
Vistin Pharma ASA had revenue of 115.04M NOK in the quarter ending March 31, 2025, with 10.74% growth. This brings the company's revenue in the last twelve months to 440.66M, down -0.14% year-over-year. In the year 2024, Vistin Pharma ASA had annual revenue of 429.50M, down -2.01%.
Revenue (ttm)
440.66M
Revenue Growth
-0.14%
P/S Ratio
2.47
Revenue / Employee
6.04M
Employees
75
Market Cap
1.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 429.50M | -8.83M | -2.01% |
| Dec 31, 2023 | 438.33M | 133.48M | 43.78% |
| Dec 31, 2022 | 304.85M | 26.23M | 9.41% |
| Dec 31, 2021 | 278.62M | 24.72M | 9.73% |
| Dec 31, 2020 | 253.91M | 25.78M | 11.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 603.92M |
| Nordhealth AS | 537.23M |
| Photocure ASA | 532.69M |
| Nykode Therapeutics AS | 104.04M |
| Hofseth BioCare ASA | 265.54M |
| Omda AS | 426.27M |
| Gentian Diagnostics ASA | 158.07M |
| ArcticZymes Technologies ASA | 102.97M |